Contact Us
Drug Search Results
More Filters [+]

Vapendavir

Alternative Names: vapendavir, BTA-798, BTA798, BTA 798
Latest Update: 2024-07-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Capsid Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vaxart
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Andrei Floroiu
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vapendavir

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease|Common Cold|Communicable Diseases|Emphysema|Enterovirus Infections|Respiratory Tract Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ALT VPV-202

P2

Recruiting

Enterovirus Infections|Respiratory Tract Infections|Common Cold|Chronic Obstructive Pulmonary Disease|Emphysema|Communicable Diseases

2024-12-30

ALT VPV-101

P1

Completed

Chronic Obstructive Pulmonary Disease

2023-12-12

Recent News Events

Date

Type

Title

05/26/2022

News Article

 Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral

05/25/2022

News Article

 Altesa BioSciences Recognizes Co-Founder and Partner for Major NIH Research Grant to Discover New Antiviral Drugs

02/28/2022

News Article

 Altesa BioSciences Announces Scientific Advisory Board

02/10/2022

News Article

 Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Global Viral Threats

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions